Elexacaftor / Ivacaftor / Tezacaftor Dosage
Medically reviewed by Drugs.com. Last updated on Dec 1, 2023.
Applies to the following strengths: 50 mg-37.5 mg-25 mg and ivacaftor 75 mg; 100 mg-75 mg-50 mg and ivacaftor 150 mg; 80 mg-60 mg-40 mg and ivacaftor 59.5 mg; 100 mg-75 mg-50 mg and ivacaftor 75 mg
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Cystic Fibrosis
Morning dose: 2 tablets (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally once a day
Evening dose: 1 tablet (of ivacaftor 150 mg) orally once a day
Comments:
- Doses should be taken approximately 12 hours apart and administered with fat-containing food.
- If genotype is unknown, a US FDA-cleared cystic fibrosis (CF) mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data.
Use: For the treatment of CF in patients who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.
Usual Pediatric Dose for Cystic Fibrosis
2 TO LESS THAN 6 YEARS:
Weight less than 14 kg:
- Morning dose: 1 packet of granules (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) orally once a day
- Evening dose: 1 packet of granules (containing ivacaftor 59.5 mg) orally once a day
Weight 14 kg or greater:
- Morning dose: 1 packet of granules (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally once a day
- Evening dose: 1 packet of granules (containing ivacaftor 75 mg) orally once a day
6 TO LESS THAN 12 YEARS:
Weight less than 30 kg:
- Morning dose: 2 tablets (of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg) orally once a day
- Evening dose: 1 tablet (of ivacaftor 75 mg) orally once a day
Weight 30 kg or greater:
- Morning dose: 2 tablets (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally once a day
- Evening dose: 1 tablet (of ivacaftor 150 mg) orally once a day
12 YEARS AND OLDER:
- Morning dose: 2 tablets (of elexacaftor 100 mg/ tezacaftor 50 mg/ivacaftor 75 mg) orally once a day
- Evening dose: 1 tablet (of ivacaftor 150 mg) orally once a day
Comments:
- Doses should be taken approximately 12 hours apart and administered with fat-containing food; oral granules should be premixed in soft foods or liquids.
- If genotype is unknown, a US FDA-cleared cystic fibrosis (CF) mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data.
Use: For the treatment of CF in patients who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on in vitro data
Renal Dose Adjustments
MILD TO MODERATE RENAL DYSFUNCTION (CrCl 30 mL/min/1.73 m2 or greater): No adjustment recommended
SEVERE RENAL DYSFUNCTION (CrCl less than 30 mL/min/1.73 m2) or ESRD: Use with caution; data not available
Liver Dose Adjustments
MILD LIVER DYSFUNCTION (Child-Pugh A): No adjustment recommended
MODERATE LIVER DYSFUNCTION (Child-Pugh B): Not recommended unless clear medical need and benefit exceeds risk. If administered, use with caution at a reduced dose based on the following age/weight parameters:
AGE 2 TO LESS THAN 6 YEARS:
Weight less than 14 kg:
- Days 1 to 3: One packet of granules (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) orally once a day
- Day 4: No dose
- Days 5 and 6: One packet of granules (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) orally once a day
- Day 7: No dose
- Repeat weekly dosing schedule; no evening dose of ivacaftor oral granules should be taken on any day.
Weight 14 kg or greater:
- Days 1 to 3: One packet of granules (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally once a day
- Day 4: No dose
- Days 5 and 6: One packet of granules (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally once a day
- Day 7: No dose
- Repeat weekly dosing schedule; no evening dose of ivacaftor oral granules should be taken on any day.
AGE 6 TO LESS THAN 12 YEARS:
Weight less than 30 kg:
- Day 1: Two tablets (of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg) orally in the morning
- Day 2: One tablet (of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg) orally in the morning
- Repeat alternating daily dosing schedule; no evening dose of ivacaftor tablets should be taken on any day.
Weight 30 Kg Or More:
- Day 1: Two tablets (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning
- Day 2: One tablet (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning
- Repeat alternating daily dosing schedule; no evening dose of ivacaftor tablets should be taken on any day.
AGE 12 YEARS OR OLDER:
- Day 1: Two tablets (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning
- Day 2: One tablet (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning
- Repeat alternating daily dosing schedule; no evening dose of ivacaftor tablets should be taken on any day.
SEVERE LIVER DYSFUNCTION (Child-Pugh C): Not recommended; drug exposure is expected to be higher.
RECOMMENDATIONS FOR TRANSAMINASE ELEVATIONS DURING THERAPY:
- For ALT or AST elevations greater than 5 times the upper limit of normal [5 x ULN], or ALT or AST elevations to greater than 3 x ULN with bilirubin greater than 2 x ULN): Interrupt dosing of this drug and closely follow laboratory tests until abnormalities resolve.
- Once transaminase elevations resolve, the benefits and risks of resuming treatment should be considered.
Comments:
- Closely monitor liver function tests in patients with mild to moderate liver dysfunction who use this drug.
Dose Adjustments
COADMINISTRATION WITH MODERATE CYP450 3A INHIBITORS (e.g., fluconazole, erythromycin):
AGE 2 TO LESS THAN 6 YEARS:
Weight less than 14 kg:
- Day 1: One packet of granules (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) orally in the morning
- Day 2: One packet of granules (containing ivacaftor 59.5 mg) orally in the morning
- Repeat alternating daily dosing schedule; no evening dose of ivacaftor oral granules should be taken.
Weight 14 kg or more:
- Day 1: One packet of granules (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning
- Day 2: One packet of granules (containing ivacaftor 75 mg) orally in the morning
- Repeat alternating daily dosing schedule; no evening dose of ivacaftor oral granules should be taken.
AGE 6 TO LESS THAN 12 YEARS:
Weight less than 30 kg:
- Day 1: Two tablets (of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg) orally in the morning
- Day 2: One tablet (of ivacaftor 75 mg) orally in the morning
- Repeat alternating daily dosing schedule; no evening dose of ivacaftor tablets should be taken.
Weight 30 kg or more:
- Day 1: Two tablets (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning
- Day 2: One tablet (of ivacaftor 150 mg) orally in the morning
- Repeat alternating daily dosing schedule; no evening dose of ivacaftor tablets should be taken.
AGE 12 YEARS OR OLDER:
- Day 1: Two tablets (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning
- Day 2: One tablet (of ivacaftor 150 mg) orally in the morning
- Repeat alternating daily dosing schedule; no evening dose of ivacaftor tablets should be taken.
COADMINISTRATION WITH STRONG CYP450 3A INHIBITORS (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin):
AGE 2 TO LESS THAN 6 YEARS:
Weight less than 14 kg:
- Morning dose: One packet of granules (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) orally in the morning twice a week, about 3 to 4 days apart.
- Evening dose: None
Weight 14 kg or more:
- Morning dose: One packet of granules (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning twice a week, about 3 to 4 days apart.
- Evening dose: None
AGE 6 TO LESS THAN 12 YEARS:
Weight less than 30 kg:
- Morning dose: Two tablets (of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg) orally in the morning twice a week, about 3 to 4 days apart.
- Evening dose: None
Weight 30 kg or more:
- Morning dose: Two tablets (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning twice a week, about 3 to 4 days apart.
- Evening dose: None
AGE 12 YEARS OR OLDER:
- Morning dose: Two tablets (of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally in the morning twice a week, about 3 to 4 days apart.
- Evening dose: None
CONCOMITANT ADMINISTRATION WITH STRONG CYP450 3A INDUCERS: Not Recommended
Comments:
- Avoid food or drink containing grapefruit during therapy.
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 2 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- For oral use; morning and evening doses should be administered approximately 12 hours apart.
- Each dose should be taken with fat-containing food (e.g., meals or snacks prepared with butter/oils, or containing eggs, peanut butter, cheeses, nuts, whole milk, or meats).
- TABLETS: Swallow whole.
- ORAL GRANULES: Premix with soft food or liquid; administer immediately before or after ingestion of fat-containing food.
Missed dose:
- If 6 hours or LESS have passed since the missed morning or evening dose: Take missed dose as soon as possible and continue on original schedule.
- If MORE than 6 hours have passed since the missed morning dose: Take the missed morning dose as soon as possible and skip the evening dose; resume usual dosing schedule the following morning.
- If MORE than 6 hours have passed since the missed evening dose: Skip the missed evening dose; resume usual dosing schedule the following morning.
- The morning and evening doses should not be taken at the same time.
Storage requirements:
- Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).
Reconstitution/preparation:
PACKET OF ORAL GRANULES:
- Mix entire contents of each packet of with one teaspoon (5 mL) of age-appropriate soft food or liquid at room temperature or below.
- Examples of soft food or liquids include pureed fruits/vegetables, yogurt, applesauce, water, milk, or juice.
- Once mixed, the product should be consumed completely within 1 hour.
- Consult the manufacturer product information for detailed preparation instructions.
General:
- This drug is for treatment of patients with cystic fibrosis (CF) who have at least one F508del mutation in the CF transmembrane conductance regulator (CFTR) gene OR a mutation that is responsive based on in vitro data; if genotype is unknown, use a US FDA-cleared CF mutation test prior to initiating therapy.
- This combination product is supplied as fixed-dose combination (elexacaftor/tezacaftor/ivacaftor) tablets OR oral granule packets, co-packaged with single ingredient (ivacaftor) tablets OR oral granule packets.
- Food or drink containing grapefruit should be avoided during treatment.
Monitoring:
- Hepatic: Liver function tests, including ALT, AST, and bilirubin (prior to therapy, every 3 months during the first year, and annually thereafter; more frequent testing should be considered in patients with a history of hepatobiliary disease or elevated liver function tests)
- Ocular: Ophthalmological examinations in pediatric patients (at baseline and follow-up)
Patient advice:
- Read the US FDA-approved patient labeling (Patient Information).
- Take doses with fat containing foods approximately 12 hours apart; understand what do in case of a missed dose.
- Inform your health care provider of any history of liver disease or liver test abnormalities.
- Discontinue use of this drug immediately if signs/symptoms of a hypersensitivity reactions occur.
- Understand that there are a number of drug interactions that may affect the efficacy of therapy; report all medications, herbal supplements, and vitamins to your healthcare provider.
- Avoid food or drink containing grapefruit during therapy.
- Speak with your healthcare provider if you are pregnant/planning to become pregnant, or breastfeeding.
- Pediatric patients: Ensure baseline and follow-up eye exams are performed.
Frequently asked questions
More about elexacaftor / ivacaftor / tezacaftor
- Check interactions
- Compare alternatives
- Reviews (2)
- Side effects
- During pregnancy
- Drug class: CFTR combinations
- En español
Patient resources
- Elexacaftor, ivacaftor, and tezacaftor drug information
- Elexacaftor, tezacaftor, ivacaftor and ivacaftor (Advanced Reading)
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Zithromax
Zithromax (azithromycin) treats infections caused by bacteria, such as respiratory infections, skin ...
Creon
Creon (pancrelipase) contains digestive enzymes and is used to improve food digestion in people who ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Zenpep
Zenpep (pancrealipase) is used to replace pancreatic enzymes when the body does not have enough of ...
Vitamin e
Vitamin E is an antioxidant that occurs naturally in some foods and is used to treat or prevent ...
Pancrelipase
Pancrelipase systemic is used for chronic pancreatitis, cystic fibrosis, pancreatic exocrine dysfunction
Mannitol
Mannitol systemic is used for cerebral edema, cystic fibrosis, diagnosis and investigation, oliguria
Amikacin
Amikacin systemic is used for bacteremia, bone infection, cystic fibrosis, febrile neutropenia ...
Tobramycin
Tobramycin systemic is used for bacteremia, bacterial infection, bone infection, burns, external ...
Gentamicin
Gentamicin systemic is used for bacteremia, bacterial endocarditis prevention, bacterial infection ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.